The Latest Cardiac and Vascular News
CAMPBELL, Calif.–(BUSINESS WIRE)–Imperative Care, Inc. today announced U.S. Food and Drug Administration (FDA) 510(k) clearance and first patient cases with the latest advancement in ischemic stroke treatment – the novel Zoom 7X Catheter for aspiration thrombectomy procedures. The newest addition to the company’s comprehensive Zoom Stroke System, the Zoom 7X Catheter […]
Demonstrated at LINNC Paris 2025, the company’s latest release of SmartCT delivers fast, intelligent 3D imaging in the Angio suite — helping physicians act with greater speed and confidence during a range of critical neurovascular procedures
CAMPBELL, Calif. – Imperative Care, Inc. today announced the Zoom Stroke System has been further expanded with the launch of the Zoom DuoPort technology, which allows physicians to use the novel Continuous Dual Aspiration Technique (CDAT) on two Zoom Aspiration Catheters simultaneously from a single vacuum source. CDAT empowers physicians with enhanced […]
Reduced hospital stays with more patients discharged to home when treated with RNS60 Results presented during oral presentation at the American Academy of Neurology 2025 Annual Meeting TACOMA, Wash., April 9, 2025 /PRNewswire/ — Revalesio, a clinical-stage pharmaceutical company…
Innovative Therapy Helps Wexford Stroke Survivor Regain Hand Function and Return to Playing Guitar B-ROLL AND INTERVIEWS: https://f.io/lpCCNeXD VIDEO of Vivistim® Paired VNS System: microtransponder | Showpad PITTSBURGH, Pa., April 3, 2025 /PRNewswire/ — Stroke is a potentially…
The first patient implanted at Brown University Health marks the expansion of the study to multiple clinical sites RESTORE aims to generate the data necessary to demonstrate the long-term safety and efficacy of DBS+Rehab in stroke patients to support marketing approval CLEVELAND, March 4,…
NEW YORK, Feb. 18, 2025 /PRNewswire/ — Remedy Pharmaceuticals, a leader in stroke drug development today announced efficacy data from the Phase 2 GAMES-RP and Phase 3 CHARM studies of CIRARA (intravenous glyburide) for the treatment of Large Hemispheric Infarction (LHI) presented at the…
February 10, 2025
SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX) reported 12 month data from the Phase 2 study (SYCAMORE) of REC-994, the first industry sponsored Phase 2 trial completed in Cerebral Cavernous Malformations (CCM). The Company announced in September 2024 that the signal-finding study met its primary endpoint.
VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its wholly owned subsidiary, Algernon NeuroScience (AGN Neuro), has appointed Validcare as the contract research organization (“CRO”) for the Company’s upcoming randomized, double-blind, placebo-controlled Phase 2a DMT study of 40 stroke patients in Europe. The study is expected to begin enrolling patients in Q3 of 2025. Validcare is a leading U.S. based full service CRO with experience across a wide range of therapeutic indications.
